In almost all randomized trials that evaluated different agents or combinations in the adjuvant setting in the past decades, breast cancer was treated as a single clinical entity in terms of chemotherapy; tumor biological characteristics that were addressed for additional targeted drugs were positivity for hormone receptors (ER/PgR) and later on, HER2 protein overexpression / gene amplification. Here, ERBB2 is linked to breast cancer.